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Abstract. We will review the revolution brought about by low cost next generation sequencing in a 
wide array of diagnostic and industrial applications with a special emphasis on computational requirements 
and big data challenges.  
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1 Introduction 
Next generation sequencing ((NGS) has 
fundamentally changed modern biological research. It is, 
in fact, an excellent example of how gradual 
improvements on a powerful initial idea, Sanger’s 
original dideoxynucleotide sequencing, can lead to such 
levels of quantitative increase in data production that 
fundamentally changes a given research field.  
Virtually any nucleic acid related research question 
can be investigated in a comprehensive, high resolution 
fashion free from experimental confounding factors such 
as nucleic acid cross hybridization. This has produced a 
deluge of data on the scale of hundreds of Terabytes even 
for a single research laboratory. This review will survey 
both the various application domains of next generation 
sequencing and their associated computational and 
analytical challenges.  
2 Biochemical considerations of next 
generation sequencing 
It was recognized early on that next generation 
sequencing will allow querying both the genome (DNA) 
and the transcriptome (RNA) on a wide range of 
resolution. The exact sequence of nucleotides (e.g. single 
nucleotide polymorphisms, single nucleotide variations) 
and the overall architecture of the entire genome can be 
determined in a single experiment (one run of whole 
genome sequencing) [1].  
A wide array of starting materials can be used for next 
generation sequencing. Any form of nucleic acid (DNA 
or RNA), from any sources (from inside the cell, from 
cell free biological fluids or ancient fragmented DNA) 
can be sequenced and quantified. Nucleic acids can be 
preselected as in e.g. whole exome sequencing (exon 
capture) or by other capture mechanisms such as specific 
protein beacons in ChipSeq analysis. The variations are 
virtually unlimited and novel approaches are constantly 
being added to the toolbox of biological research. This 
universality has led to an enormous variety of application 
domains. 
3 Application domains of next generation 
sequencing 
3.1 Next generation sequencing in microbiology 
Since DNA is universal, next generation sequencing 
can be used to detect and investigate any life form from 
viruses to humans. This is readily exploited in the various 
forms of sequencing based microbial diagnostics and it 
has also led to a new research field, metagenomics [2]. 
In this, the fact that often a diverse group of microbiota 
live together as an “organic whole” has led to the 
realization that those species do not need to be isolated 
individually before sequencing, but the pooled DNA can 
be sequenced together and the sequence tags can be 
“sorted out” after the sequencing reaction. This 
ingenious idea has led to significant advances in our 
understanding of, for example, the microbial community 
of our gut flora. This method also allows monitoring 
sewage quality and may help to monitor and prevent 
disease outbreaks. 
3.2 Next generation sequencing in human diseases 
Genome wide association studies are a powerful 
method to identify germline variants associated with 
increased disease risk.  
Remarkably, germline DNA of the fetus can be 
efficiently detected in maternal blood, leading to the 
powerful tool of  prenatal testing  [3]. By this, genomic, 
chromosomal aberrations of the fetus can be detected 
without virtually any risk to the mother or the fetus.  
Proceedings of the XIX International Conference 
“Data Analytics and Management in Data Intensive 
Domains” (DAMDID/RCDL’2017), Moscow, Russia, 
October 10–13, 2017 
3
3.3 Next generation sequencing in cancer 
Cancer is a genetic disease. Accumulating mutations 
at various levels of the germline genome lead to 
malignant transformation. It is therefore, obvious, that 
one of the main targets of next generation sequencing is 
cancer diagnostics. Both germline and somatic mutations 
are readily identified by NGS. A great number of 
oncogenic mutations, many of them targetable by 
therapy, have thus been identified [4]. NGS data also 
allow us to reconstruct the evolutionary history of cancer, 
an issue of potentially great significance [5]. 
Recently, sequence analysis of liquid biopsies, 
essentially cell free DNA obtained from various bodily 
fluids, emerged as a minimally invasive tool to obtain 
vital information about the presence of cancer in a patient 
individual before or during therapy. 
4 Computational and analytical challenges 
of next generation sequencing data 
The uniform nature of the biochemical reactions and 
ingenuity of technical development has led to an 
unexpected situation. The price drop/throughput increase 
of next generation sequencing has significantly outpaced 
Moore’s law over the past decade. Therefore, next 
generation sequencing has become more of a 
computational rather than a biochemical problem. The 
speed of data accumulation is so fast that data storage and 
data analysis is becoming a more and more challenging 
problem in modern sequencing based projects. Whole 
genome sequencing on a single cancer sample can easily 
take up hundreds of GBs of data storage. Therefore, a 
single study, such as the one analyzing the whole genome 
of 560 breast cancer cases [6], can easily produce data on 
at the level of hundreds of Terabytes. Such amount of 
data cannot possibly be downloaded for reanalysis in an 
efficient manner, therefore alternative solutions, such as 
cloud based computing had to be found. 
Management of vast amounts of data is only one, 
mainly technical aspect of the challenges at hand. 
While next generation sequencing based genomics 
easily qualifies as one of the main areas of big data 
science, in many aspects it is also markedly different 
from those. While in, e.g., financial data the individual 
variables are connected by poorly understood causative 
factors and in physics the entire data space is regulated 
by well defined, homogenous laws of physics, in 
biology, genomics the situation lies somewhere in 
between. Variables, such as genes, proteins etc. are 
connected by the principles of physical chemistry, but the 
actual parameters of those significantly vary across the 
various pairs of biological entities. This fact places the 
analysis of biological systems in the realm of robust, 
complex systems for which the analytical principles are 
poorly understood. Therefore, in order to effectively 
analyze the massive amounts of genomic information 
one needs to “front-load” the computational analysis 
with as much biological knowledge as possible.  
We will present several strategies along those lines. In 
particular, we will discuss how genomics, next 
generation sequencing based whole genome analysis 
helps us to understand DNA repair pathway aberrations, 
and their diagnostic and therapeutic implications in 
cancer. We will also discuss how genomics is exploited 
to understand the main principles of therapeutic immune 
responses against cancer and how genomics, machine 
learning and high throughput screening are combined in 
an interdisciplinary environment to design effective 
vaccines against cancer. 
5 The industrial impact of next generation 
sequencing 
In order to satisfy the need for NGS based diagnostics 
a whole industry has developed during the past decade. 
Conferences such as the 2017 Next Generation Dx 
Summit, (http://www.nextgenerationdx.com) provide an 
excellent overview of the major trends and players. 
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